Bio-Rad Laboratories Inc.
BIO | NYSE
$371.84
-$0.34 (-0.09%)
Nov 2, 2026, 11:56 AM ET · Market open
Company Profile
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Key Executives
| Name | Position |
|---|---|
| Norman D. Schwartz | Chairman & Chief Executive Officer |
| Jonathan DiVincenzo | President & Chief Operating Officer |
| Roop K. Lakkaraju | Executive Vice President & Chief Financial Officer |
| Courtney C. Enloe | Executive Vice President, General Counsel & Secretary |
| James J. Barry | Executive Vice President & President of Life Science Group |
| Matthew Werner | Senior Vice President and Chief Compliance & Privacy Officer |
| Michael Crowley | Executive Vice President of Global Commercial Operations |
| Nanditha R. Yelamanchi | Executive Vice President of Global Human Resources |
| Rajat Mehta | Executive Vice President of Global Commercial Operations |
| Ruben Argueta | Vice President of Investor Relations |
Bio-Rad Laboratories Inc.
| Country | United States |
| IPO Date | Feb 27, 1980 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 7,450 |
| CEO | Norman D. Schwartz |
Contact Details
1000 Alfred Nobel Drive Hercules,
California 94547 United States
Stock Details
| Ticker Symbol | BIO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000012208 |
| CUSIP Number | 090572207 |
| ISIN Number | US0905722072 |
| SIC Code | 3826 |
Recent News
- 5 days ago / globenewswire.comBIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government's National Security Ecosystem
- 12 days ago / globenewswire.comBIO-key Secures Another Middle East Government Contract for its Passwordless, Biometric, Identity and Access Management Solutions
- 17 days ago / gurufocus.comBio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still Overvalued -- GF Score: 73/100
- 19 days ago / businesswire.comBio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
- 20 days ago / globenewswire.comBIO-key Names Cybersecurity Veteran Stephen Morrow President of PortalGuard to Drive Accelerated Adoption of its Innovative IAM Solution
- 20 days ago / globenewswire.comBIO-key Adds New Middle East Government Security Agency Customer, Expanding Regional Footprint
- 26 days ago / globenewswire.comArtelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
- 28 days ago / globenewswire.comPDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
- 1 month ago / globenewswire.comBIO-key Partners with Al Majlis Group to Expand Identity Security Across Arabian Gulf
- 1 month ago / marketbeat.comBio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Add to Watchlist
Select watchlists to add or remove BIO